# Optimizing Treatment for Treatment-Experienced, HIV-Infected People

> **NCT00537394** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 517 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Enfuvirtide
- **DRUG:** Raltegravir
- **DRUG:** Darunavir
- **DRUG:** Tipranavir
- **DRUG:** Etravirine
- **DRUG:** Maraviroc

## Key facts

- **NCT ID:** NCT00537394
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2012-05
- **Final completion:** 2013-04
- **Target enrollment:** 517 (ACTUAL)
- **Last updated:** 2021-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00537394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00537394, "Optimizing Treatment for Treatment-Experienced, HIV-Infected People". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00537394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*